Abstract 91P
Background
Immune Checkpoint inhibitors (ICI) administration at home is considered as a development priority by the French society of cancer immunotherapy and French government with “ma santé 2022” program. The study objective was to analyze the territorial development of ICI infusions at home between 2021 and 2022.
Methods
The national hospital databases from the French statutory health insurance were used to identify all patients treated by ICI and to build a cohort of patients with at least one administration in Hospitalization At Home (HAH). All ICI administrations were collected retrospectively up to 2016. A descriptive analysis was performed to characterize patients, centers and "HAH patients" care pathways (based on treatment sequences clustering algorithms) and administration costs in the French statutory health insurance perspective.
Results
Over 2021 and 2022, 652 ICI (0.6%) patients were treated in HAH. Primary diagnosis among HAH patients were lung cancer with 51% (26%-78% depending on regions), followed by metastatic melanoma with 17%, (1%-18%). The three main regions were Ile de France (IDF), Auvergne Rhône Alpes (AURA) and Nouvelle Aquitaine (NA), with 543 patients (83% of HAH patients). The proportion of HAH patients per region varied from 0.1% to 1.6%. Mean age were similar between regions in main indications, from 65 to 69 years old in lung cancer regions and 68 in metastatic melanoma regions. Men proportion varied in lung cancer (6.6% - 31.8%) and were similar in metastatic melanoma (38.1% - 40.5%). Care pathways’ characteristics and costs per HAH infusion in main indications heavily differed per region (Table). Table: 91P
HAH patients’ and care pathways’ characteristics, and cost of HAH infusion, in the 3 main regions per indication
Regions | N | Mean Duration (±STD) 1st DCU - 1st HAH (days) | Mean Karnofsky Score (±STD) | Cost per infusion (€) | |
Lung | IDF | 80 | 346 (±378) | 57 (±7) | 314 (±213) |
AURA | 101 | 255 (±205) | 74 (±12) | 401 (±1480) | |
NA | 105 | 270 (±337) | 63 (±13) | 325 (±685) | |
France | 330 | 304 (±342) | 64 (±13) | 346 (±901) | |
Metastatic melanoma | IDF | 27 | 351 (±379) | 58 (±4) | 268 (±18) |
AURA | 27 | 513 (±523) | 73 (±8) | 311 (±113) | |
Occitanic | 6* | - | - | - | |
France | 69 | 381 (±433) | 64 (±10) | 290 (±86) |
STD: Standard Deviation * <11 patients : sample results not presented
Conclusions
Patient pathways depended on indication and differed according to regions. Further analyses on healthcare resources will allow to understand how optimizing HAH use for ICI patients in France.
Legal entity responsible for the study
Bristol Myers Squibb.
Funding
Bristol Myers Squibb.
Disclosure
A.C. Toffart, G. Casanova: Financial Interests, Personal, Advisory Board: BMS. M. Pierre, H. Lemasson, V. Moreau-Mallet, M. Chartier: Financial Interests, Personal, Affiliate: BMS. N. Pagès, R. Jolivel, A. Panès: Financial Interests, Personal, Financially compensated role: BMS. M. Pérol: Financial Interests, Personal, Advisory Board, Advisory Board: Roche, AstraZeneca, MSD, BMS, Lilly, Novartis, Takeda, Gritstone, Sanofi, Pfizer, Amgen, Janssen, GSK, Eisai, Ipsen, Novocure, AbbVie, Anheart Therapeutics, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker, Symposium: Roche, AstraZeneca, MSD, BMS, Boehringer Ingelheim, Takeda, Illumina, Pfizer, Medscape; Financial Interests, Personal, Advisory Board, Expert Testimony: AstraZeneca; Financial Interests, Personal, Steering Committee Member, Steering Committee Member: Lilly; Financial Interests, Institutional, Local PI, Local PI: AbbVie, Amgen, Anheart Therapeutics, Apollomics, Arrivent Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Innate Pharma, Roche; Financial Interests, Institutional, Research Grant, Research Grant: AstraZeneca, Boehringer Ingelheim, Roche, Takeda; Financial Interests, Personal, Trial Chair, Trial Chair: Anheart Therapeutics; Financial Interests, Personal, Steering Committee Member, Idmc Chair: PharmaMar, Sophiagenetics; Financial Interests, Personal, Steering Committee Member, Steering Committee Member: Roche; Financial Interests, Personal, Other, DMSB: Roche.
Resources from the same session
53P - Novel ex-vivo manufacturing of transiently expressed armoured CAR T cells for glioblastoma
Presenter: Saket Srivastava
Session: Poster Display session
Resources:
Abstract
54P - Superior antitumor activities of fourth-generation CAR-T cells containing three costimulatory domains targeting GD2-positive tumors
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
55P - Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment
Presenter: Marta Soria Castellano
Session: Poster Display session
Resources:
Abstract
56P - Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
57P - SENDER™ Directed LNP Delivery of mRNA for In Situ generation of highly potent CAR T Cells
Presenter: Biao Ma
Session: Poster Display session
Resources:
Abstract
58P - Cardiovascular outcomes of novel CAR-T cell therapies: A meta-analysis of incidence, risk factors, and management of cardiotoxicity
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
59P - Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
Presenter: Nicolas Mach
Session: Poster Display session
Resources:
Abstract
60P - Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
61P - Optimized protocol for the accelerated production of dendritic cell-derived exosomes (DEXs): Achieving speed without compromising efficacy
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
62P - Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells
Presenter: Sumei Chen
Session: Poster Display session
Resources:
Abstract